Immunotherapy, a revolutionary approach in cancer treatment, has significantly altered the landscape of oncology. By harnessing the body's immune system, it targets cancer cells more precisely, mitigating the systemic side effects commonly associated with traditional therapies. This article aims to elucidate the fundamental aspects of immunotherapy for physicians.
Immunotherapy works on the principle of enhancing the body's natural defenses to fight cancer. It uses substances made in the body or in a laboratory to improve or restore immune system function. There are several types of immunotherapy, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and others.
Monoclonal antibodies are immune system proteins produced in the lab, designed to attach to specific targets found on cancer cells. They can mark cancer cells so the immune system can find and destroy them. Immune checkpoint inhibitors, on the other hand, help the immune system recognize and attack cancer cells. They block proteins that stop the immune system from attacking cancer cells.
Cancer vaccines are substances introduced into the body to cause an immune response against certain diseases. They can be used to prevent or treat cancer. Other immunotherapies include T-cell therapy and immune system modulators. T-cell therapy involves altering the genes in a patient's T cells to help them attack cancer cells. Immune system modulators enhance the body's immune response against cancer.
Immunotherapy has ushered in a new era in cancer treatment, offering hope to patients with previously untreatable cancers. As our understanding of the immune system advances, so too will the sophistication and efficacy of immunotherapies. It is crucial for physicians to stay abreast of these developments to provide the best care for their patients.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation